RWA Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
RWA Wealth Partners's REGN Position: Q2 2026 in Review
RWA Wealth Partners increased its Regeneron Pharmaceuticals (REGN) stake by 24% in Q2 2026, buying an estimated $64.7K and bringing the position to 493 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #564.
RWA Wealth Partners first reported a position in REGN in Q2 2018 and has held it in 19 quarters since. The position peaked at $13.1M in Q4 2024. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- RWA Wealth Partners held 493 shares of Regeneron Pharmaceuticals worth $307K as of Q2 2026.
- RWA Wealth Partners bought 95 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $64.7K.
- Regeneron Pharmaceuticals made up ﹤0.01% of RWA Wealth Partners's portfolio in Q2 2026, its #564 holding.
- RWA Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
- RWA Wealth Partners's Regeneron Pharmaceuticals position peaked at $13.1M in Q4 2024.
- 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on RWA Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.